Move out to of our nominees that are currently pending before the committee. We obviously have to have the requisite number of members here. So until such time as we have a quorum, we will move to our scheduled full Committee Hearing on infrastructure permitting, if were able to get the quorum of 12 we will take up the businessman at that point in time. I would anticipate that it would be relatively quick. So with that, we have names on the table in front of us, but i would invite you each to come to the table as a provide an opening statement. Mr. Casing, ms. Fleagle, astroturfing, mr. Brown, ms. Caruso and mr. Russell if just want to join us there. We are here today to discuss infrastructure permitting challenges ongoing efforts to streamline federal approvals and opportunities to improve the responsiveness, the transparency and the predictability of our system of permit review. I think we all recognize the need to make investments that will both upgrade and modernize our infrastruct
The National Institute of health and dr. Scott gottlieb, the commissioner of food and drug. Well have as i mentioned to senator murphy, well have a hearing next wednesday on another important part of the cures act which was the first reorganization of our Mental Health laws in a decade which senator cassidy and senator murphy played a major role in. Senator murray and i will have each an Opening Statement then well introduce our panel of witnesses. Our witnesses will have five minutes of questions. In 2007 doug oliver who is in the front row, i believe, a Computer Programmer began to have trouble seeing and after a near accident had his drivers license taken away and was declared legally behind. The culprit was a rare form of macular degeneration. Doug moved to nashville where his doctor told him while there were no cures, doug could Search Online for a Clinical Trial. Doug found a rejen tiff medicine Clinical Trial in florida where doctors took cells out of the bone marrow in his hip,
[ is distinct conversations ]. And live here this morning on c spann span 3, a discussion about transparency and oversight at the food and Drug Administration. Well be hearing from dr. Scott gottlieb starting off the conference. Introductions under way. Efforts to pass and implement the food safety modernization act, focus on medical devices, especially the potential of using the unique device identifier to improve monitoring devices throughout the product lifecycle. We have successfully worked on products 10 to courage innovation particularly around antibiotics and 10 to sure appropriate use of them. We focused on drug safety and transparency in the supply chain and especially on the safety of compounded drugs. Among other things, pew submitted transparency to the task force back in 2010 if the. They touch on some of the topics well be discussing today. Reading the background papers for todays meet regular mind med of a meeting we convened in a room directly above of us here a few yea
Process to approve new drugs. This is 35 minutes. Thanks a lot. Thanks for the opportunity to be here today. We had a dialogue over many years, and i appreciate the relationship we had talking about policy issues. I wrote a subsequent article saying whats taking you so long, josh. So ive been waiting for him to return the favor, and i just got a copy of it. So i appreciate it very much. Thanks for the opportunity to be here today. Thanks john hopkins for hoestin this, and pew for providing space. Transparency can be a powerful tool for innovation. New platforms for visualizing large complex data sets present important new opportunities for the research and Development Community for regulators and for clinicians. It allows people to harness data to advance the safe and effective and Efficient Development for medical needs and to communicate information supporting regulatory Decision Making in ways that engender Greater Public confidence in those decisions. The fdas goal is to advance tr
I wrote a subsequent article saying whats taking you so long, josh. So ive been waiting for him to return the favor, and i just got a copy of it. So i appreciate it very much. Thanks for the opportunity to be here today. Thanks john hopkins for hoestin this, and pew for providing space. Transparency can be a powerful tool for innovation. New platforms for visualizing large complex data sets present important new opportunities for the research and Development Community for regulators and for clinicians. It allows people to harness data to advance the safe and effective and Efficient Development for medical needs and to communicate information supporting regulatory Decision Making in ways that engender Greater Public confidence in those decisions. The fdas goal is to advance transparency without reducing incentives to innovate. This can be accomplished by meeting our statutory responsibility for protecting confidential, commercial information, trade secrets and private data while dissemi